Loading...
Market
Story
UK Patient First to Receive Experimental Lung Cancer Vaccine in Global Trial
Aug 23, 2024, 04:19 AM
A lung cancer patient in the UK has become the first to receive an experimental vaccine as part of a world-first trial. This pioneering trial, conducted across seven countries, aims to explore new treatments for lung cancer. The patient, whose cancer was found by coincidence, received the vaccine at UCLH. This development offers hope in the fight against the disease, marking a significant step in medical research. The trial has garnered attention and is featured on the front page of several publications, highlighting its potential impact on future cancer treatments.
View original story
Similar markets
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
No countries • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
More than 10 countries • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
UK • 14%
Germany • 14%
USA • 14%
France • 14%
Italy • 14%
Spain • 14%
Other • 14%
0-2 countries • 25%
3-5 countries • 25%
6-8 countries • 25%
9 or more countries • 25%
China • 25%
India • 25%
Brazil • 25%
Other • 25%
Significant survival improvement • 25%
Partial survival improvement • 25%
No significant change • 25%
Deterioration • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
None • 25%
Europe • 25%
Asia • 25%
Both Europe and Asia • 25%